Turin, Italy – 19 June 2025
Continue readingKither Biotech and Pantherna Therapeutics Announce Strategic Collaboration on Synergistic mRNA and Peptide Therapies for Genetic Lung Diseases
Turin (Italy) / Hennigsdorf (Germany), 08.01.2026
Continue readingKither Biotech Announces Phase 1 Clinical Study Of KIT2014, A Novel Inhaled Peptide Therapy For Cystic Fibrosis
Turin, Italy – October 30, 2024 – Kither Biotech, a clinical-stage biotech company focused on innovative therapies for respiratory diseases, today announced the start of a Phase 1 clinical study of KIT2014, a novel inhaled peptide therapy for Cystic Fibrosis (CF).
Continue readingKither Biotech Announces Appointment of Dr. Dimitrios Goundis to Board of Directors
Turin, Italy, 13 November 2023 – Kither Biotech (“Kither” or “the Company”), a pioneering biopharmaceutical firm committed to developing novel therapies for rare respiratory diseases, is pleased to announce the addition of Dr. Dimitrios Goundis to its Board of Directors.
Continue readingKither Biotech announces publication of new data in Science Translational Medicine
Turin, Italy, 31 March 2022 – Data support the use of Kither Biotech’s lead asset, KIT2014, in obstructive airway diseases…
Continue readingKither Biotech Raises €18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer
Turin, Italy, 16 March 2022 – Kither Biotech (“Kither” or “the Company”), a biopharmaceutical company developing novel therapies for rare respiratory diseases…
Continue readingKither Biotech raises a €5.6m financing round to support the clinical development of a new drug for cystic fibrosis and other pulmonary diseases
Turin, Italy, 5 July 2019 – Kither Biotech raises a €5.6m financing round to support the clinical development of a new drug for cystic fibrosis and other pulmonary diseases
Continue reading